Figure 1: Identification of antibodies specific for the MUC1 100mer vaccine peptide isolated from a vaccinated donor using NGS/LC-MS/MS. | Scientific Reports

Figure 1: Identification of antibodies specific for the MUC1 100mer vaccine peptide isolated from a vaccinated donor using NGS/LC-MS/MS.

From: Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential

Figure 1

(a) Phylogenetic dendrogram of variable region sequences. Each unique antibody chain is identified by its CDR3 sequence, and chains that generated active antibodies are indicated with an identifier number next to the CDR sequence. The scale indicates the rate of nucleotide substitution per-site in each tree. The V gene family of each cluster is indicated. (b) ELISAs testing antibody binding to immobilized MUC1 100mer vaccine peptide. Assays were performed in triplicate and results are shown as absorbances at 450 nm ± S.D. Human IgG mAb “hIgG anti-CMV”, specific for a glycoprotein from Cytomegalovirus was used as a non-specific antibody binding control26.

Back to article page